Unpacking the Genetics of Friedreich’s Ataxia
Arnulf Koeppen, MD
Friedreich’s Ataxia: Impact of Frataxin Loss
BCMA mRNA CAR-T Shows Durable Benefit in MG
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
FA hiPSCs in Translational Drug Development
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
11:45 AM - 12:45 PM ET
Orlando, Florida
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
Aaron Miller, MD
Addressing Social and Systemic Barriers in Schizophrenia
Shelina Ramnarine, PhD
Margaret Emerson, DNP, APRN, PMHNP-BC
Nutrition and the Gut-Brain Connection in Schizophrenia
Deanna L. Kelly, PharmD, BCPP
Depression as a Signal of MS Progression
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Minimal By Design: Define MSE Endpoints
The IgG Clock: Redose Using IgG Kinetics
Loading...
We're glad to see you're enjoying Global Neurology Academy… but how about a more personalized experience?
Press cancel to remain on Global Neurology Academy. Press the link below or the continue button to keep going.